Obbligazioni societarie HIGH YIELD e oltre, verso frontiere inesplorate - Vol. 2

:reading:

Teva: Here's Why The Future Is Different For This Troubled Pharmaceutical Giant - Teva Pharmaceutical Industries Limited (NYSE:TEVA) | Seeking Alpha

"The failed acquisitions by past management regimes have put a tremendous burden on Teva and as a result, the company has no financial flexibility. In these next couple of years, management has little room for error."

"Its load of nearly $29 billion in debt is concerning and if the generic drug market does not recover soon, the company will be in serious trouble. However, those risks are why Teva is trading just 6 times next year’s earnings and at one of the lowest valuations in the history of the company. Teva is a great investment right now."
 
Ultima modifica:

Users who are viewing this thread

Back
Alto